Cost of MS Study in Czech Republic

Eva Havrdová
Jana Blahová-Dušánková
Tomáš Kalinčík
Co-workers from 6 Czech MS Center
Consultants: Gisela Kobelt, Tomas Doležal

Charles University, First Medical Faculty,
Dpt. of Neurology
Praha, Czech Republic
permanent disability

RR-MS

SP-MS

treatment effect (1)
treatment effect (2)
treatment effect (???)

t

clinical

silent

Axonal loss
Negotiations for reimbursement:

- European Code of Good Practice
- National societies of professionals
- National patient organizations

Help:
- pharmacoeconomic data
- scientific data on early treatment (what is lost is not regained),
- placebo controlled randomized trials,
- international guidelines (included in the Code)
- PR strategies
Progression of **untreated** MS

Natural course: Time to EDSS = 6 (n=902)

Conversion of RR MS into progressive MS

<table>
<thead>
<tr>
<th>MS duration in yrs</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>1–5</td>
<td>12.1</td>
</tr>
<tr>
<td>6–10</td>
<td>41.3</td>
</tr>
<tr>
<td>11–15</td>
<td>57.6</td>
</tr>
<tr>
<td>16–25</td>
<td>65.6</td>
</tr>
<tr>
<td>26+</td>
<td>88.9</td>
</tr>
</tbody>
</table>

Adapted by permission of Oxford University Press from Weinshenker BG et al. *Brain*. 1989;112:133-146.
Split of average costs (10 EU countries, G. Kobelt, 2006)
Cost of MS studies v EU

- EDSS 0-3: 22 000 € / yr
- EDSS 4-6.5: 45 000 € / yr
- EDSS 7-9.5: 75 000 € / yr

European Brain Council
Average yearly cost of MS = 31 000 €
(adjustment for purchasing power parity)

Kobelt, Jan 2009
Eur Health Economics
Total cost of MS in EU, Sobocki P, MSJ 2007
Czech Republic: First pharmacoeconomic data (1996-9) after first 2 yrs of DMD Tx (150 pt)

◆ Relapse rate decreased by 69%

◆ No of hospital admissions due to acute attacks decreased by 80%

= Step 1
Step 2: Determination of costs of MS in CZ (Cost of MS Study, COMS)

- prospective pharmacoeconomic study

Ambitious project created after discussions with Gisela Kobelt:

3 mos of retrospective and 3 mos of prospective follow-up of all health and social care costs incl. working capacity losses

Study started autumn 2005, first part finished 2/2009
We plan to repeat the survey in 5 years
Demography of patients enrolled in COMS

- 904 patients in total, 658 females, 246 males

- Age: $37.3 \pm 16.3$

- MS duration since diagnosis: $8.3 \pm 7.5$

- EDSS: $3.3 \pm 2.2$
  - 0-3.5: 676
  - 4-6.5: 235
  - 7-10: 80
RESULTS……

727 000 CZK = 29445 Euro
Employed ............. pensioned

- Employed
- Student
- Maternity leave
- Unemployed-no pension
- Unemployed+pension
The message for the society and health care providers:

This is the first real life pharmacoeconomic study in Central Europe

showing clearly:

IT IS WORTH OF INVESTING INTO MS RIGHT AT THE TIME OF DIAGNOSIS

WAITING FOR DISABILITY COSTS MORE
Never ever give up hope!